

57



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/730,379	12/09/2003	Barton F. Haynes	1579-871	2849
23117	7590	09/29/2005	EXAMINER	
NIXON & VANDERHYE, PC 901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203			KIM, YUNSOO	
			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 09/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/730,379

Applicant(s)

HAYNES, BARTON F.

Examiner

Yunsoo Kim

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 August 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: _____

200

DETAILED ACTION

1. Applicants' response to Restriction Requirement and cancellation of non-elected claims filed on 8/5/05 is acknowledged.

Applicants' election of Group I with traverse, claims 1-9 drawn to a method of enhancing vaccine-induced is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). The requirement is still deemed proper and is therefore made FINAL.

Accordingly, claims 1-9 are pending and being examined.

2. Sequence Compliance: The instant application appears to be in sequence compliance for patent application containing amino acid sequence disclosures.

3. Acknowledgment is made of applicant's claim for domestic priority under 35 U.S.C. 119(e).

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "sufficient to effect" recited in claim 1 is ambiguous and unclear and the metes and bounds of the claimed "sufficient to effect" is not defined.

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1644

7. Claims 1-9 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of enhancing an immune response with a polypeptide consisting of extracellular domain of K12, does not reasonably provide enablement for any method of enhancing an immune response comprising “portion” of K12, 95% homologous to extracellular domain of K12 and mimetic thereof as recited in claim 1. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use of the invention commensurate in scope with these claims.

The specification disclosure does not enable one skilled in the art to practice the invention without any undue amount of experimentation.

Factors to be considered in determining whether undue experimentation is required to practice the claimed invention are summarized *In re Wands* (858 F2d 731, 737, 8 USPQ2d 1400, 1404 (Fed.Cir.1988)). The factors most relevant to this rejection are the scope of the claim, the amount of direction or guidance provided, the lack of sufficient working examples, the unpredictability in the art and the amount of experimentation required to enable one of the skilled in the art to practice the claimed invention.

The phrases “portion of K12”, 95% homologous to extracellular domain of K12 and mimetic thereof have not provided sufficient biochemical information that distinctly identify a vaccine composition comprising of polypeptide of K12 other than the vaccine composition comprising of K12 polypeptide consisting of extracellular domain. The specification fails to provide sufficient guidance and direction as to how the skilled artisan can make such compositions comprising portion of K12, 95% homologous to extracellular domain of K12 and mimetic, commensurate in scope with the claimed invention.

The specification fails to provide any guidance on how to make and use the vaccine composition comprising any K12 portion, 95% homologous to extracellular domain of K12 peptide or mimetic thereof.

Minor structural differences among structurally related compounds or compositions can result in substantially different or deleterious biological activities.

Art Unit: 1644

Ngo *et al* teach that the amino acid positions within the polypeptide/protein that can tolerate change such as conservative substitution or no substitution, addition or deletion which are critical to maintain the protein's structure will require guidance (see Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495 in particular).

In re Fisher, 166 USPQ 18 indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. Since the amino acid sequence of a polypeptide determined its structural property, predictability of which amino acid fragment can retain the functional capabilities of the "portion of K12", 95% homologous to extracellular domain of K12 and mimetic thereof comprising polypeptide requires knowledge of, and guidance with regard to, which segments in the polypeptide's sequence contribute to its function.

Therefore, there is insufficient direction as to how to make and to use a vaccine composition comprising any "portion of K12", 95% homologous to extracellular domain of K12 and mimetic thereof which can be used as to whether such a desired effect can be achieved or predicted, as encompassed by the claims.

In view of the quantity of experimentation necessary, the limited working example, the unpredictability of the art, the lack of sufficient guidance in the specification, and the breadth of the claims, it would take undue trials and errors to practice the claimed invention.

8. Claims 1-9 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant is in possession of a vaccine composition comprising of the peptide consisting of extracellular domain of K12; however, applicant is not in possession of a vaccine composition comprising "portion of K12", 95% homologous to extracellular domain of K12 and mimetic thereof.

There is insufficient written description encompassing "portion of K12", 95% homologous to extracellular domain of K12 and mimetic thereof of isolated peptide because any chemical or physical properties (i.e. chemical structure or specific amino acid changes lead to said function) of "portion of

Art Unit: 1644

K12", 95% homologous to extracellular domain of K12 and mimetic thereof are not set forth in the specification as filed, commensurate in scope with the claimed invention. Claims 1-9 read on any portion of K12, and mimetics include any small molecules increase stability of soluble but Applicant fails to disclose even a single species within the genus claimed. Therefore, Applicant does not possess of scope of claimed invention. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of use.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the written description inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116). Consequently, Applicant was not in possession of the instant claimed invention. See University of California v. Eli Lilly and Co. 43 USPQ2d 1398.

Applicant is directed to the Revised Interim Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001.

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

10. Claims 1-9 are rejected under 35 U.S.C. 102 (e) as being anticipated by U.S. Pat. No. 6,762,030 B2.

Art Unit: 1644

The '030 patent teaches a method of administering soluble human K12 to mammal to induce interferon gamma production, NK cell proliferation (i.e. enhancing immune response, col. 9, lines 36-59), K12 fusion proteins (i.e. K12-poly-His Flag, K12/hu IgG, Fig 2, col. 3-4 overlapping paragraph) and the therapeutic uses can be extended to human (col. 17, lines 41-60).

The '030 patent further teaches the soluble K12 may include the homologous analogs (col. 6, lines 26-46) and nucleic acid that encodes proteins including vector (col. 10, lines 41-45).

As evidenced in specification of the instant application (p. 6, lines 26-28) and specification of U.S. Pat. No. 6,762,030 (col. 6, lines 4-7), the soluble K12 lacks the functional trans-membrane domain and includes the entire extracellular domain of human K12 and the referenced limitation of soluble K12 reads on extracellular domain that would bind CD7.

Claim 9 is included because the reference teaches "vector" and the nucleic acid encodes protein and any nucleic acid vector intends to produce protein has an operable promoter.

The prior art teachings thus anticipate the instant claimed invention.

11. No claims are allowable.


12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yunsoo Kim whose telephone number is 571-272-3176. The examiner can normally be reached on Monday thru Friday 8:30 - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yunsoo Kim
Patent Examiner
Technology Center 1600
September 20, 2005


Patrick J. Nolan, Ph.D.
Primary Examiner
Technology Center 1600